Anti-Obesity Drugs Market Size, Share, Industry, Forecast and Outlook (2024-2031)

Anti-Obesity Drugs Market

Global Anti-Obesity Drugs Market Surpasses $2.5 Billion in 2022, Projected to Reach $43.7 Billion by 2030 with a Remarkable CAGR of 45.5%

The Global Anti-Obesity Drugs Market has achieved significant growth, reaching a valuation of US$ 2.5 billion in 2022, and is anticipated to surge to US$ 43.7 billion by 2030, reflecting a remarkable Compound Annual Growth Rate (CAGR) of 45.5% during the forecast period from 2024 to 2031.

Market Overview

Obesity, a critical health concern characterized by an excess accumulation of body fat, has become a global epidemic, necessitating effective pharmaceutical interventions. The Anti-Obesity Drugs Market responds to this urgency by offering medications designed to aid individuals struggling with obesity. These drugs operate by suppressing appetite, enhancing metabolism, or impeding the absorption of fat from food.

Driving Forces

The market's robust growth is propelled by several factors, including the escalating global obese population, heightened awareness, and continuous product introductions. Additionally, research endeavors for novel drug developments, coupled with strategic market activities such as mergers, expansions, acquisitions, and collaborations among industry players, contribute to the burgeoning demand.

Market Scope and Metrics

CAGR: 45.5%
Size Available for Years: 2021-2030
Forecast Period: 2024-2031
Data Availability: Value (US$)
Segments Covered: Mechanism of Action, Drug Type, Route of Administration, Distribution Channel, and Region
Regions Covered: North America, Europe, Asia-Pacific, South America, and Middle East & Africa
Fastest Growing Region: Asia-Pacific
Largest Region: North America

Report Insights Covered

The comprehensive market report includes in-depth analyses, encompassing Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and Acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, Porter's Analysis, Pricing Analysis, Regulatory Analysis, Supply-Chain Analysis, and Other key Insights.

To know more Insights Download Sample. : https://www.datamintelligence.com/download-sample/anti-obesity-drugs-market

Market Dynamics

The Growing Obese Population Drives the Growth of the Anti-Obesity Drugs Market

The escalating global obese population is anticipated to be a key driver for the Anti-Obesity Drugs Market during the forecast period. According to the World Obesity Atlas 2022, over 1 billion individuals globally are projected to be living with obesity by 2030.

In March 2022, the World Health Organization (WHO) highlighted that over 1 billion people worldwide are overweight, emphasizing the urgency of addressing this health crisis. Subsequent reports from the World Obesity Federation forecast that more than 4 billion individuals, half the world's population, are expected to be obese by 2035.

Increasing Research Activities for Anti-obesity Drugs Present Growth Opportunities

The Anti-Obesity Drugs Market is poised to benefit from increasing research activities. For example, Innovent Biologics reported positive outcomes from its Phase II clinical trial of IBI362, a dual agonist, demonstrating the potential of such developments in obesity treatment.

High Drug Cost Hinders Market Growth

Despite the promising prospects, the high cost of anti-obesity drugs poses a challenge to market growth. For instance, the four-week course of Wegovy comes with a substantial cost, potentially hindering widespread accessibility.

Segment Analysis

Prescription Drugs to Dominate Market

The prescription drugs segment is projected to hold approximately 57.8% of the global market share, driven by increased product approvals. Notably, regulatory authorities such as the European Committee for Medicinal Products for Human Use (CHMP) and the U.S. Food and Drug Administration have endorsed key medications for chronic weight management.

Geographical Share

North America Estimated to Hold 38.3% Market Share by 2030

Owing to the rising obese population, North America is poised to dominate the global market, holding an estimated 38.3% market share by 2030. Reports from organizations like Trust for America's Health and the Centers for Disease Control and Prevention (CDC) underscore the severity of the obesity epidemic in the region.

Key Players

Major global players contributing to the Anti-Obesity Drugs Market include Eli Lilly and Company, Bayer AG, Bristol-Myers Squibb, Currax Pharmaceuticals LLC, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Merck & Co. Inc., Norgine BV, Novo Nordisk AS, and Pfizer Inc., among others.

Rlated Reports:

systemic juvenile idiopathic arthritis market https://www.datamintelligence.com/research-report/systemic-juvenile-idiopathic-arthritis-market
secondary hyperparathyroidism treatment market https://www.datamintelligence.com/research-report/secondary-hyperparathyroidism-treatment-market
hemophilia a treatment market https://www.datamintelligence.com/research-report/hemophilia-a-treatment-market
drug resistant epilepsy market https://www.datamintelligence.com/research-report/drug-resistant-epilepsy-market
rosai dorfman disease market https://www.datamintelligence.com/research-report/rosai-dorfman-disease-market
opioid use disorder drugs market https://www.datamintelligence.com/research-report/opioid-use-disorder-drugs-market

Contact Us -
Company Name: DataM Intelligence
Email: info@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence 4Market Research is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.